First-in-Human PET Imaging of Prostate Cancer Using [68Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [68Ga]Ga-AZ-NI-093.
Аннотация
Our team previously reported a preclinical study of 2 novel prostate-specific membrane antigen (PSMA)-targeted compounds that incorporate a hypoxia-sensitive nitroimidazole (NI) moiety-6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid-PSMA-093 (AZ-093) and its hypoxia-responsive derivative 6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid-NI-PSMA-093 (AZ-NI-093). This prospective trial aims to evaluate the clinical value of both agents in patients with prostate cancer, specifically exploring the impact of NI on tumor uptake.
Methods
Sixty patients were enrolled in this PET/CT imaging study. Thirty patients underwent a head-to-head comparison of [68Ga]Ga-AZ-093 with [68Ga]Ga-PSMA-11 or [68Ga]Ga-PSMA-617, and 30 patients underwent a head-to-head comparison of [68Ga]Ga-AZ-NI-093 with [68Ga]Ga-AZ-093. The number of tumors and SUV for tumors and organs were measured and recorded. SUVmax differences between [68Ga]Ga-AZ-NI-093 and [68Ga]Ga-AZ-093 PET/CT were calculated for further analysis. Immunohistochemical staining for hypoxia-inducible factor 1 was performed on 12 surgical specimens of intraprostatic tumors.
Results
All patients tolerated [68Ga]Ga-based PET/CT scans without adverse effects. The initial biodistribution of [68Ga]Ga-AZ-093 and [68Ga]Ga-AZ-NI-093 in humans, as assessed by PET/CT, was comparable to that of other PSMA-targeted radiopharmaceuticals, with respective effective absorbed doses of 0.0128 ± 0.00594 and 0.0160 ± 0.000869 mSv/MBq. [68Ga]Ga-AZ-093 exhibited higher tumor uptake 60 min after injection compared with [68Ga]Ga-PSMA-11 (SUVmax, 22.2 ± 10.8 vs. 20.4 ± 14.8; P = 0.025) and [68Ga]Ga-PSMA-617 (SUVmax, 20.1 ± 12.7 vs. 10.8 ± 8.7; P < 0.001), while maintaining comparable tumor detection rates. [68Ga]Ga-AZ-NI-093 showed further improved tumor uptake relative to [68Ga]Ga-AZ-093 at 60 min (SUVmax, 17.8 ± 14.0 vs. 16.3 ± 11.5; P = 0.009) and 150 min (31.3 ± 18.5 vs. 28.7 ± 17.5; P = 0.003), especially in large-volume, high-grade intraprostatic tumor and metastatic sites. The expression of hypoxia-inducible factor 1 in tumors, as an indicator of hypoxia, demonstrated a significant association with International Society of Urological Pathology grade (r = 0.519; P = 0.038) and difference in SUVmax (r = 0.629; P = 0.023).
Conclusion
Both [68Ga]Ga-AZ-093 and [68Ga]Ga-AZ-NI-093 represent promising PSMA-targeted radiopharmaceuticals. [68Ga]Ga-AZ-NI-093 demonstrated potential in targeting hypoxic tumor tissues. Future studies with larger sample sizes are needed to further explore the clinical value of these radiopharmaceuticals.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.